Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-09-16
|
Xultophy®/IDegLira (combination of insulin degludec (Tresiba®) and liraglutide (Victoza®)) |
type 2 diabetes |
3b |
Novo Nordisk (Denmark) |
Metabolic diseases |
2016-09-16
|
IMM-101 (heat killed whole cell mycobacterium obuense) |
advanced pancreatic cancer |
2 |
Immodulon Therapeutics (UK) |
Cancer - Oncology |
2016-09-15
|
GSK3326595 |
solid tumors, non-Hodgkin's lymphoma |
1 |
GSK (UK) |
Cancer - Oncology |
2016-09-15
|
ertugliflozin |
type 2 diabetes |
3 |
Merck&Co (USA - NJ) Pfizer (USA - NY) |
Metabolic diseases |
2016-09-15
|
ABO-102 (SC AAV-SGSH) |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
preclinical |
Abeona Therapeutics (USA - NY) |
Rare diseases - Genetic diseases |
2016-09-15
|
SFX-01 |
multiple sclerosis |
preclinical |
Evgen Pharma (UK) |
Neurodegenerative diseases |
2016-09-15
|
|
familial chylomicronemia syndrome |
|
Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) |
Rare diseases - Genetic diseases |
2016-09-15
|
benralizumab |
asthma |
3 |
AstraZeneca (UK) |
Allergic diseases – Inflammatory diseases – Respiratory diseases |
2016-09-15
|
Zinbryta™ (Daclizumab High-Yield Process - DAC HYP) |
relapsing-remitting multiple sclerosis |
3 |
BiogenIdec (USA - MA) AbbVie (USA - IL) |
Neurodegenerative diseases |
2016-09-15
|
ZW25 - anti-HER2 bispecific antibody |
HER2-expressing tumors |
1 |
Zymeworks (Canada) |
Cancer - Oncology |
2016-09-14
|
GBT440 |
hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis |
preclinical |
Global Blood Therapeutics (USA - CA) |
Lung diseases - Respiratory diseases - Rare diseases |
2016-09-14
|
binimetinib, encorafenib and cetuximab |
metastatic colorectal cancer (mCRC) |
3 |
Array BioPharma (USA - CO) Pierre Fabre (France) Merck KGaA (Germany) |
Cancer - Oncology |
2016-09-14
|
MD1003 (high doses of pharmaceutical-grade biotin) |
adrenoleukodystrophy |
preclinical |
Medday (France) |
Rare diseases - Genetic diseases |
2016-09-14
|
GMI-1271 |
multiple myeloma |
1 |
GlycoMimetics (USA - Md) |
Cancer - Oncology |
2016-09-13
|
NeuVax™ (nelipepimut-S) |
ovarian cancer, pancreatic cancer |
preclinical |
Galena Biopharma (USA - OR) |
Cancer - Oncology |
2016-09-13
|
inecalcitol |
acute myeloid leukemia (AML) |
2 |
Hybrigenics (France) |
Cancer - Oncology |
2016-09-12
|
bacteriophage cocktail against Clostridium difficile |
Clostridium difficile infections |
preclinical |
AmpliPhi BioSciences (USA - VA) Leicester University (UK) |
Infectious diseases |
2016-09-12
|
Generx® [Ad5FGF-4] gene therapy |
myocardial ischemia and refractory angina due to advanced coronary artery disease |
3 |
Angionetics (USA - CA) Huapont Life Sciences Affiliate (China) |
Cardiovascular diseases |
2016-09-12
|
Livatag® (doxorubicin Transdrug®) |
hepatocellular carcinoma |
preclinical |
Onxeo (France) |
Cancer - Oncology |
2016-09-09
|
Zalmoxis® (investigational cell therapy product TK) |
high-risk leukemia |
3 |
MolMed (Italy) |
Cancer - Oncology |